Forkhead box J1 expression is upregulated and correlated with prognosis in patients with clear cell renal cell carcinoma

Zhu,Pingyu; Piao,Yongrui; Dong,Xiuzhe; Jin,Zhehu

doi:10.3892/ol.2015.3376

Forkhead box J1 expression is upregulated and correlated with prognosis in patients with clear cell renal cell carcinoma

Authors:
- Pingyu Zhu
- Yongrui Piao
- Xiuzhe Dong
- Zhehu Jin
View Affiliations

Affiliations: Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637200, P.R. China, Department of Urology, Affiliated Hospital of Yanbian University, Yanji, Jilin 133000, P.R. China, Department of Dermatology and Venereology, Affiliated Hospital of Yanbian University, Yanji, Jilin 133000, P.R. China
Published online on: June 16, 2015 https://doi.org/10.3892/ol.2015.3376
Pages: 1487-1494

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The forkhead box (FOX) family of transcription factors are considered to have a role in tumorigenesis. FOXJ1 is a member of the FOX family; however, its function in human renal cell carcinoma (RCC) has remained to be elucidated. Therefore, the present study evaluated the expression of FOXJ1 in human clear cell RCC and the effect of FOXJ1 on the proliferative ability of RCC cells. The RCC specimens analyzed in the present study were obtained from 286 patients with RCC who underwent nephrectomy. FOXJ1 mRNA expression levels were determined using reverse transcription‑quantitative polymerase chain reaction, and FOXJ1 protein expression levels were determined using immunohistochemistry and western blot analysis. To determine the effect of FOXJ1 on the proliferative ability of RCC cells, the expression of FOXJ1 was decreased using small interfering (si)RNA, and a FOXJ1 vector was stably transfected into RCC cell lines. The proliferative ability of RCC cells was then examined using a WST‑1 assay and xenograft experiments with BALB/c nude mice, where the association between FOXJ1 expression and patient survival was determined using Kaplan‑Meier analysis. FOXJ1 expression was significantly higher in RCC tissues compared with that of healthy renal tissues. Furthermore, FOXJ1 expression was associated with tumor stage, histologic grade and size. In addition, FOXJ1 significantly enhanced the proliferation of RCC cells in vitro and in vivo. The present study identified that FOXJ1 expression was upregulated in RCC and enhanced the proliferative ability of RCC cells. Therefore, FOXJ1 may serve as an independent prognostic marker and a therapeutic target for the treatment of patients with RCC.

View Figures

View References

1	Deng FM and Melamed J: Histologic variants of renal cell carcinoma: does tumor type influence outcome? Urol Clin North Am. 39:119–132. 2012. View Article : Google Scholar : PubMed/NCBI
2	Athar U and Gentile TC: Treatment options for metastatic renal cell carcinoma: a review. Can J Urol. 15:3954–3966. 2008.PubMed/NCBI
3	Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
4	Yu DS, Chang SY and Ma CP: The expression of mdr-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines. Br J Urol. 82:544–547. 1998. View Article : Google Scholar : PubMed/NCBI
5	Hartmann JT and Bokemeyer C: Chemotherapy for renal cell carcinoma. Anticancer Res. 19:1541–1543. 1999.PubMed/NCBI
6	Sciarra A, Gentile V, Salciccia S, Alfarone A and Di Silverio F: New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): Current status and future prospects. Rev Recent Clin Trials. 3:97–103. 2008. View Article : Google Scholar : PubMed/NCBI
7	Dalle S, Thieblemont C, Thomas L and Dumontet C: Monoclonal antibodies in clinical oncology. Anticancer Agents Med Chem. 8:523–532. 2008. View Article : Google Scholar : PubMed/NCBI
8	Coppin C: Immunotherapy for renal cell cancer in the era of targeted therapy. Expert Rev Anticancer Ther. 8:907–919. 2008. View Article : Google Scholar : PubMed/NCBI
9	Simpson D and Curran MP: Temsirolimus: In advanced renal cell carcinoma. Drugs. 68:631–638. 2008. View Article : Google Scholar : PubMed/NCBI
10	Myatt SS and Lam EW: The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859. 2007. View Article : Google Scholar : PubMed/NCBI
11	Jackson BC, Carpenter C, Nebert DW and Vasiliou V: Update of human and mouse forkhead box (FOX) gene families. Hum Genomics. 4:345–352. 2010.PubMed/NCBI
12	Wonsey DR and Follettie MT: Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res. 65:5181–5189. 2005. View Article : Google Scholar : PubMed/NCBI
13	Kim IM, Ackerson T, Ramakrishna S, et al: The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res. 66:2153–2161. 2006. View Article : Google Scholar : PubMed/NCBI
14	Lee JS, Chu IS, Heo J, et al: Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 40:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
15	Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP and Quinn AG: FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res. 62:4773–4780. 2002.PubMed/NCBI
16	Kalin TV, Wang IC, Ackerson TJ, et al: Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res. 66:1712–1720. 2006. View Article : Google Scholar : PubMed/NCBI
17	Yoshida Y, Wang IC, Yoder HM, Davidson NO and Costa RH: The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. Gastroenterology. 132:1420–1431. 2007. View Article : Google Scholar : PubMed/NCBI
18	Laoukili J, Kooistra MR, Brás A, et al: FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol. 7:126–136. 2005. View Article : Google Scholar : PubMed/NCBI
19	Costa RH: FoxM1 dances with mitosis. Nat Cell Biol. 7:108–110. 2005. View Article : Google Scholar : PubMed/NCBI
20	Wang X, Kiyokawa H, Dennewitz MB and Costa RH: The Forkhead Box m1b transcription factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration. Proc Natl Acad Sci USA. 99:16881–16886. 2002. View Article : Google Scholar : PubMed/NCBI
21	Wang IC, Chen YJ, Hughes D, et al: Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol. 25:10875–10894. 2005. View Article : Google Scholar : PubMed/NCBI
22	Accili D and Arden KC: FoxOs at the crossroads of cellular metabolism, differentiation and transformation. Cell. 117:421–426. 2004. View Article : Google Scholar : PubMed/NCBI
23	Hu MC, Lee DF, Xia W, et al: IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell. 117:225–237. 2004. View Article : Google Scholar : PubMed/NCBI
24	Seoane J, Le HV, Shen L, Anderson SA and Massagué J: Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell. 117:211–223. 2004. View Article : Google Scholar : PubMed/NCBI
25	Modur V, Nagarajan R, Evers BM and Milbrandt J: FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem. 277:47928–47937. 2002. View Article : Google Scholar : PubMed/NCBI
26	Parry P, Wei Y and Evans G: Cloning and characterization of the t(X;11) breakpoint from a leukemic cell line identify a new member of the forkhead gene family. Genes Chromosomes Cancer. 11:79–84. 1994. View Article : Google Scholar : PubMed/NCBI
27	Ward EC, Hoekstra AV, Blok LJ, et al: The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma. Endocrinology. 149:1942–1950. 2008. View Article : Google Scholar : PubMed/NCBI
28	Goto T, Takano M, Albergaria A, et al: Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene. 27:9–19. 2008. View Article : Google Scholar : PubMed/NCBI
29	Nucera C, Eeckhoute J, Finn S, et al: FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res. 15:3680–3689. 2009. View Article : Google Scholar : PubMed/NCBI
30	Lin L, Miller CT, Contreras JI, et al: The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Res. 62:5273–5279. 2002.PubMed/NCBI
31	Sano H, Leboeuf JP, Novitskiy SV, et al: The Foxc2 transcription factor regulates tumor angiogenesis. Biochem Biophys Res Commun. 392:201–206. 2010. View Article : Google Scholar : PubMed/NCBI
32	Brody SL, Yan XH, Wuerffel MK, Song SK and Shapiro SD: Ciliogenesis and left-right axis defects in forkhead factor HFH-4-null mice. Am J Respir Cell Mol Biol. 23:45–51. 2000. View Article : Google Scholar : PubMed/NCBI
33	Hackett BP, Brody SL, Liang M, Zeitz ID, Bruns LA and Gitlin JD: Primary structure of hepatocyte nuclear factor/forkhead homologue 4 and characterization of gene expression in the developing respiratory and reproductive epithelium. Proc Natl Acad Sci USA. 92:4249–4253. 1995. View Article : Google Scholar : PubMed/NCBI
34	Clevidence DE, Overdier DG, Tao W, et al: Identification of nine tissue-specific transcription factors of the hepatocyte nuclear factor 3/forkhead DNA-binding-domain family. Proc Natl Acad Sci USA. 90:3948–3952. 1993. View Article : Google Scholar : PubMed/NCBI
35	Li CS, Zhang Q, Lim MK, et al: Association of FOXJ1 polymorphisms with systemic lupus erythematosus and rheumatoid arthritis in Korean population. Exp Mol Med. 39:805–811. 2007. View Article : Google Scholar : PubMed/NCBI
36	Li CS, Chae SC, Lee JH, Zhang Q and Chung HT: Identification of single nucleotide polymorphisms in FOXJ1 and their association with allergic rhinitis. J Hum Genet. 51:292–297. 2006. View Article : Google Scholar : PubMed/NCBI
37	Srivatsan S and Peng SL: Cutting edge: Foxj1 protects against autoimmunity and inhibits thymocyte egress. J Immunol. 175:7805–7809. 2005. View Article : Google Scholar : PubMed/NCBI
38	Lin L, Brody SL and Peng SL: Restraint of B cell activation by Foxj1-mediated antagonism of NF-kappa B and IL-6. J Immunol. 175:951–958. 2005. View Article : Google Scholar : PubMed/NCBI
39	Demircan B, Dyer LM, Gerace M, Lobenhofer EK, Robertson KD and Brown KD: Comparative epigenomics of human and mouse mammary tumors. Genes Chromosomes Cancer. 48:83–97. 2009. View Article : Google Scholar : PubMed/NCBI
40	Chen HW, Huang XD, Li HC, et al: Expression of FOXJ1 in hepatocellular carcinoma: correlation with patients' prognosis and tumor cell proliferation. Mol Carcinog. 52:647–659. 2013. View Article : Google Scholar : PubMed/NCBI
41	Elmore JM, Kadesky KT, Koeneman KS and Sagalowsky AI: Reassessment of the 1997 TNM classification system for renal cell carcinoma. Cancer. 98:2329–2334. 2003. View Article : Google Scholar : PubMed/NCBI
42	Hong SK, Jeong CW, Park JH, Kim HS, Kwak C, Choe G, Kim HH and Lee SE: Application of simplified Fuhrman grading system in clear-cell renal cell carcinoma. BJU Int. 107:409–415. 2011. View Article : Google Scholar : PubMed/NCBI
43	Abourbih S, Sircar K, Tanguay S, Kassouf W, Aprikian A, Mansure J and Brimo F: Aldehyde dehydrogenase 1 expression in primary and metastatic renal cell carcinoma: an immunohistochemistry study. World J Surg Oncol. 11:2982013. View Article : Google Scholar : PubMed/NCBI
44	Dutta KK, Nishinaka Y, Masutani H, et al: Two distinct mechanisms for loss of thioredoxin-binding protein-2 in oxidative stress-induced renal carcinogenesis. Lab Invest. 85:798–807. 2005. View Article : Google Scholar : PubMed/NCBI
45	Bustin SA, Benes V, Garson JA, et al: The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 55:611–622. 2009. View Article : Google Scholar : PubMed/NCBI
46	Goldman LA, Cutrone EC, Kotenko SV, Krause CD and Langer JA: Modifications of vectors pEF-BOS, pcDNA1 and pcDNA3 result in improved convenience and expression. Biotechniques. 21:1013–1015. 1996.PubMed/NCBI